What is Genomenon?
Genomenon operates at the intersection of artificial intelligence and clinical genomics. By systematically organizing the world's genomic knowledge, the company provides clinicians and researchers with the tools necessary to interpret complex genetic data with unprecedented speed and accuracy. Recognized as a Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan, Genomenon has established itself as an essential infrastructure provider for precision medicine. Its platform is designed to connect patient-specific genetic variants to peer-reviewed scientific literature, thereby streamlining the diagnostic process for rare genetic diseases and cancer. This capability is increasingly vital as the healthcare industry shifts toward personalized treatment models that rely heavily on high-fidelity genomic insights.
How much funding has Genomenon raised?
Genomenon has raised a total of $33.3M across 5 funding rounds:
Angel/Seed
$1.8M
Debt
$150K
Series A
$5.3M
Series B
$20M
Stock/Share Issuance
$6M
Angel/Seed (2016): $1.8M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Series A (2021): $5.3M supported by Red Cedar Ventures and Michigan Rise
Series B (2022): $20M featuring BroadOak Capital Partners, Riverine Ventures, Spring Mountain Capital, and Beringea
Stock/Share Issuance (2026): $6M, investors not publicly disclosed
Key Investors in Genomenon
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies, focusing on life sciences tools and diagnostics.
Spring Mountain Capital
Spring Mountain Capital specializes in various investment strategies including growth equity and private capital, providing expansion capital for enterprise technology and healthcare companies.
Beringea
Beringea is an international venture capital firm that invests in high-growth businesses in the US and UK, focusing on empowering entrepreneurs to build billion-dollar companies.
What's next for Genomenon?
With the support of this major enterprise-level funding, Genomenon is poised to scale its operations and expand its footprint in the global clinical genomics market. The strategic allocation of this capital will likely focus on enhancing the AI engine's predictive capabilities and broadening the scope of its genomic database to include more diverse patient populations. As the company moves beyond its current growth phase, it is expected to deepen its partnerships with pharmaceutical developers and diagnostic laboratories, further cementing its position as a cornerstone of modern healthcare technology. The focus remains on reducing the diagnostic odyssey for patients while providing the pharmaceutical industry with the high-quality data required to develop targeted, life-saving therapies.
See full Genomenon company page
